scholarly article | Q13442814 |
P356 | DOI | 10.1016/S0264-410X(97)00002-9 |
P698 | PubMed publication ID | 9269057 |
P2093 | author name string | Walsh EE | |
Falsey AR | |||
P2860 | cites work | Respiratory syncytial virus and influenza A infections in the hospitalized elderly | Q34300993 |
Acute upper respiratory tract viral illness and influenza immunization in homes for the elderly | Q36505063 | ||
Immunological Principles and Emerging Strategies of Vaccination for the Elderly | Q36728309 | ||
Antibody induction by influenza vaccines in the elderly: a review of the literature | Q38719169 | ||
Influenza in the elderly: report of an outbreak and a review of vaccine effectiveness reports | Q39731078 | ||
An epidemic of respiratory syncytial virus in elderly people: clinical and serological findings | Q40765474 | ||
An outbreak of an influenza-like illness in a nursing home | Q43474495 | ||
Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. | Q45765792 | ||
Respiratory syncytial virus or influenza? | Q45783418 | ||
Can respiratory syncytial virus and influenza A be distinguished clinically in institutionalized older persons? | Q45784353 | ||
Concurrent respiratory syncytial virus and influenza A infections in the institutionalized elderly and chronically ill. | Q45791213 | ||
Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level | Q45792098 | ||
Immunity to and frequency of reinfection with respiratory syncytial virus | Q45853042 | ||
Efficacy of an influenza hemagglutinin-diphtheria toxoid conjugate vaccine in elderly nursing home subjects during an influenza outbreak | Q57110756 | ||
Viral Respiratory Infections in the Institutionalized Elderly: Clinical and Epidemiologic Findings | Q67755051 | ||
Immunogenicity of new virosome influenza vaccine in elderly people | Q72683571 | ||
P433 | issue | 10 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 1130-1132 | |
P577 | publication date | 1997-07-01 | |
P1433 | published in | Vaccine | Q7907941 |
P1476 | title | Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly | |
P478 | volume | 15 |
Q45382330 | A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age. |
Q37252918 | A novel influenza virus hemagglutinin-respiratory syncytial virus (RSV) fusion protein subunit vaccine against influenza and RSV |
Q35874598 | A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines |
Q33782438 | Active and passive immunisation against respiratory syncytial virus |
Q33975799 | Active immunization in the United States: developments over the past decade |
Q33765654 | Advances in prevention of respiratory syncytial virus infections |
Q36652379 | An Ethical Justification for Expanding the Notion of Effectiveness in Vaccine Post-Market Monitoring: Insights from the HPV Vaccine in Canada |
Q36500189 | An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice |
Q34313560 | Animal pneumoviruses: molecular genetics and pathogenesis |
Q36005114 | Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains |
Q43979004 | Comparison of respiratory syncytial virus humoral immunity and response to infection in young and elderly adults |
Q44480572 | Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals |
Q35077892 | Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice |
Q45742833 | Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H. |
Q58662033 | Ethical considerations in post-market-approval monitoring and regulation of vaccines |
Q44621708 | Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults |
Q35634929 | Human metapneumovirus fusion protein vaccines that are immunogenic and protective in cotton rats |
Q90681995 | Impact of Respiratory Syncytial Virus Infection on the Host Cell: Implications for Antiviral Strategies |
Q34059447 | Impaired immune response to vaccination against infection with human respiratory syncytial virus at advanced age |
Q37501634 | Maternal transfer of RSV immunity in cotton rats vaccinated during pregnancy |
Q34990420 | Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease |
Q36005960 | Novel antigens for RSV vaccines |
Q37626071 | Novel therapies for an old virus: treatment of RSV infections in the 21st Century |
Q37568127 | Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys |
Q34342190 | Prevention of respiratory syncytial virus infections |
Q35566601 | Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years |
Q38617302 | Recent advances in the development of subunit-based RSV vaccines. |
Q33718366 | Recent developments in the biology of respiratory syncytial virus: are vaccines and new treatments just round the corner? |
Q33849224 | Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge |
Q45747454 | Respiratory syncytial and other virus infections in persons with chronic cardiopulmonary disease |
Q40836386 | Respiratory syncytial virus (RSV) disease and prospects for its control |
Q33961877 | Respiratory syncytial virus infection in adults |
Q30351086 | Respiratory syncytial virus infection in elderly adults. |
Q33588916 | Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment |
Q35102554 | Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh |
Q56481283 | Respiratory syncytial virus vaccine development |
Q84854616 | Respiratory syncytial virus vaccine development |
Q37481336 | Respiratory syncytial virus vaccine: Is it coming? |
Q43617842 | Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines |
Q33975330 | Respiratory syncytial virus vaccines |
Q34133038 | Respiratory syncytial virus vaccines for otitis media |
Q33834945 | Respiratory viral infections in the elderly |
Q36258838 | Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phas |
Q45745318 | The cost-effectiveness of a hypothetical respiratory syncytial virus vaccine in the elderly |
Q40933366 | The preventive effect of vaccine prophylaxis on severe respiratory syncytial virus infection: A meta-analysis. |
Q33558356 | Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice |
Q51724252 | Vaccine prevention of acute otitis media. |
Q78073627 | [Vaccines against respiratory syncytial virus] |
Search more.